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Abstract: The receptor for urokinase plasmino-
gen activator (uPAR; CD87) is a 50- to 65-kDa
glycosylphosphatidylinositol (GPI)-anchored glyco-
protein expressed by leukocytes and tumor cells
where it facilitates uPA-dependent, plasmin-medi-
ated pericellular proteolysis during cellular inva-
sion. Because uPAR is inducibly shed into culture
supernatants and human body fluids, we tested the
hypothesis that soluble uPAR (suPAR) can bind to
the plasma membrane of hematopoietic cells where
it might modulate their invasive phenotype. As
measured by flow cytometry, recombinant biotinyl-
ated-suPAR (B-suPAR) bound in a specific fashion
to THP-1 leukemia cells and blood PMNs and
monocytes (but not to lymphocytes). B-suPAR also
demonstrated specific binding to a variety of leuke-
mic lines, including cells that are positive or nega-
tive for membrane uPAR expression. Binding of
B-suPAR to THP-1 cells was enhanced four- to
sevenfold by 24-h exposure of cells to PMA or by
co-incubation with uPA ligand (but not its isolated
catalytic and binding fragments). Conversely, bind-
ing of B-suPAR to PMNs was unaffected by brief
exposure to fMLP, and was inhibited by co-
incubation with uPA. B-suPAR binding to PMA-
differentiated THP-1 cells in the presence of uPA
was further enhanced by acid washing (removing
endogenous uPA) but was partially inhibited by
treatment of cells with trypsin. Pretreatment of
PMA-differentiated THP-1 cells and unstimulated
PMNs with soluble sugars, calcium chelators, and
antibodies specific for integrins or extracellular
matrix proteins failed to consistently block the
binding of B-suPAR. Whereas the binding of suPAR
did not measurably affect cell-associated plasmin
activation, suPAR did competitively inhibit the
binding of exogenous uPA to membrane-associated
uPAR. These observations support the hypothesis
that suPAR can bind specifically to trypsin-sensitive
receptors expressed by certain normal and neoplas-
tic hematopoietic cells where its binding is variably
influenced by uPA ligand. J. Leukoc. Biol. 64:
203–213; 1998.
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INTRODUCTION
The receptor for urokinase plasminogen activator (uPAR;
CD87) is a 50- to 65-kDa glycosylphosphatidylinositol (GPI)-
anchored glycoprotein that is variably expressed by many
hematopoietic cells, including mononuclear phagocytes, neutro-
phils (PMNs), T lymphocytes, and eosinophils, as well as by
non-hematopoietic cells including endothelial cells, fibro-
blasts, smooth muscle cells, keratinocytes, hepatocytes, and
placental trophoblasts [reviewed in refs. 1 and 2]. The density
of plasma membrane uPAR expression on these cells is
up-regulated by a variety of activating factors, including many
inflammatory cytokines and bacterial products [e.g., lipopoly-
saccharide (LPS) and muramyl dipeptide] [3–7]. In addition to
its expression by normal cells, uPAR is found on the surface of
both hematopoietic and non-hematopoietic tumor cells. Mem-
brane uPAR is localized to the leading edge (lamellipodium) of
migrating inflammatory leukocytes and tumor cells where it
facilitates pericellular proteolysis in the path of invasion by
focusing the enzymatic activity of its bound ligand uPA to
adjacent plasminogen receptors [1, 2]. In addition to its role in
fostering the invasion of inflammatory leukocytes and tumor
cells, uPAR has been implicated in several other uPA-
dependent cellular processes including leukocyte differentia-
tion [8], tumor cell mitogenesis [9], vitronectin binding [10],
and neutrophil priming [11]. uPAR, independent of uPA, also
modulates several integrin functions including PMN/monocyte
chemotaxis [12, 13] and cellular adhesion to substrates [14,
15]. The regulation of integrin adhesive function may be one
manifestation of a symbiotic relationship between uPAR and
several members of the b1, b2, and b3 integrin families in which
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integrins, as transmembrane molecules, serve as signaling
partners for uPAR (which has no structural link to the
cytoplasm) [reviewed in refs. 16, 17]. In support of this notion,
we and others have reported a reversible physical linkage
between uPAR and integrin glycoproteins in the plasma
membrane of neutrophils, monocytes, and epithelial tumor cells
[15, 18–23].
uPAR, like several other GPI-anchored glycoproteins [24], is
shed from the surface of uPAR-expressing cells either constitu-
tively or in response to certain soluble stimuli. We have
recently reported that exposure of U-937 monocytic leukemia
cells to tumor necrosis factor a (TNF-a) is a stimulus for both
uPAR biosynthesis and shedding [25]. The physiological
relevance of this in vitro phenomenon is suggested by our
detection of a soluble form of uPAR (suPAR) in the plasma and
other body fluids of normal individuals and patients with
inflammatory conditions [26]. Normal human plasma contains
low levels of suPAR (3 6 3 ng/mL), whereas the plasma of
patients with clinical sepsis syndrome contains higher levels of
suPAR (30 6 11 ng/mL) [26]. Moreover, the extravascular
fluids (pleural, pericardial, and peritoneal) of 84 individuals
with acute and chronic inflammatory conditions contained
suPAR with a wide concentration range of 2–253 ng/mL [26].
suPAR contained within the plasma or body fluids of patients
with inflammatory conditions was functionally active as evi-
denced by its ability to bind exogenous uPA [26]. Similar
findings have been reported by Ronne [27], Pappot [28], and
Ploug [29] and their co-workers, who detected suPAR in the
sera of normal individuals and, in higher concentrations, in the
sera of patients with lung cancer and paroxysmal nocturnal
hemoglobinuria. Similarly, Pedersen et al. [30] reported the
presence of high concentrations of suPAR in the ascites fluid of
patients with ovarian carcinoma.
The phenomenon of uPAR shedding has led to the question
of what function, if any, is subserved by this molecule. The
potential physiological significance of uPAR is suggested by
the capacity of recombinant suPAR to inhibit the proliferation
and invasion of tumor cells in vitro [31, 32], to block binding of
pro-uPA to the a2 macroglobulin receptor [33], and to reconsti-
tute uPAR-dependent integrin-mediated adhesion [14]. The
first two of these activities is consistent with a scavenger
function, whereby suPAR competes with membrane uPAR for
uPA binding. However, the latter activity would seem to require
suPAR binding to the cell surface where it functions to
modulate integrin function. The capacity of soluble forms of
CD14 and CD16b (also GPI-anchored glycoproteins) to bind to
cell membranes, either emparting or modifying cellular func-
tion [34, 35], is precedent for this concept. The focus of this
study was to test the hypothesis that suPAR can indeed bind to
the plasma membrane of hematopoietic cells where it might
modulate the invasive phenotype. We found that recombinant,
biotinylated-suPAR bound in a specific fashion to THP-1
leukemia cells and to blood PMNs and monocytes. Specific
binding to THP-1 cells was enhanced by PMA-induced differ-
entiation and by co-incubation with uPA; binding to PMNs was
unaffected by activating stimuli or uPA ligand. suPAR binding
was inhibited by pretreatment of THP-1 cells with trypsin, but
its binding to THP-1 cells and PMNs was not consistently
affected by pretreatment with anti-integrin monoclonal antibod-
ies (mAb) or by sugars that inhibit linkage between uPAR and
integrins on the cell membrane.
MATERIALS AND METHODS
Monoclonal antibodies and reagents
Anti-CD11a mAb TS1/22 [36] and anti-CD18 mAb TS1/18 [36] were obtained
from the ATTC (Rockville, MD) and used in the form of ascites; IgG anti-CD11b
mAb 44 [37], anti-CD87 mAb 3B10 [38] and anti-CD11c mAb 2E1 [39] [the
hybridoma was a gift of Dr. Timothy Springer (Harvard University)] were
purified from murine ascites [38]; anti-CD11b mAb VIM12 [40] was a gift of Dr.
Walter Knapp, University of Vienna and used in the form of ascites; rabbit
polyclonal antibodies specific for vitronectin (antiserum), fibronectin (antise-
rum), and thrombospondin (IgG) were purchased from Calbiochem (San Diego,
CA). Control murine myeloma proteins IgG1, IgG2a, and IgG2b were purchased
from Cappel (West Chester, PA). Normal rabbit IgG was purified from pooled
rabbit sera. PMA, fMLP, orosomucoid, a-methyl-D-mannopyranoside, N-acetyl-
D-glucosamine (NADG), sucrose, zymosan, EGTA, and EDTA were purchased
from Sigma Chemical Corp. (St. Louis, MO). Trypsin and DNAse I were
purchased from GIBCO-BRL (Gaithersburg, MD) and Boehringer Mannheim
(Indianapolis, IN), respectively. High molecular weight (HMW) uPA, low
molecular weight (LMW) uPA, and the amino-terminal fragment (ATF) of uPA;
Spectrozyme PL; and anti-uPA antibodies were the gifts of Dr. Richard Hart,
American Diagnostica Inc. (Greenwich, CT). Streptavidin-PE (SA-PE), FITC-
conjugated goat anti-mouse, and anti-rabbit IgG were purchased from Molecu-
lar Probes (Eugene, OR), Calbiochem, and Pierce (Rockford, IL), respectively.
PI-PLC was a gift of Dr. Martin Low (Columbia University).
Production of recombinant suPAR
A stable line (a gift of Dr. Robert Cohen, Genentech) secreting truncated uPAR
was obtained by transfection of MM293 cells as previously described [41].
suPAR was purified from concentrated, serum-free conditioned medium by
affinity chromatography on ATF-Sepharose after acid-glycine elution. Purity of
suPAR was confirmed by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE), which showed a single broad band of material at approxi-
mately 50–55 kDa. Its immunological and functional activities were docu-
mented by enzyme-linked immunosorbent assay (ELISA) [26]. Biotinylation
was performed by incubating recombinant suPAR, 1 mg/mL, and sulfo-NHS-LS-
biotin (Pierce; at a molar ratio of 1:25, respectively) in 0.1 M sodium
bicarbonate, pH 8.3, on ice for 2 h. The resulting B-suPAR was dialyzed against
phosphate-buffered saline (PBS) [42].
Cells
THP-1, U-937, KG-1, KG-1a, K562, and HL-60 human myeloid leukemic cell
lines (originally obtained from ATCC) were grown in RPMI 1640 medium
(BioWhittaker, Walkersville, MD) supplemented with 2 mM L-glutamine, 10
µg/mL penicillin-streptomycin, and 10% calf serum (HyCLone Lab., Logan,
UT). In certain experiments, these cells (,0.5 3 106 mL) were cultured for 24
h at 37°C in the same medium containing 10 nM PMA. After exposure to PMA,
these THP-1 cells displayed an 11- and 7-fold increase in their expression of
CD11b and CD87, respectively (data not shown). In other experiments,
PMA-differentiated THP-1 cells were subsequently subjected to the following
conditions. Acid wash: cells were incubated for 3 min at 4°C in 50 mM glycine
and 0.1 M NaCl, pH 3.0, quenched with 0.5 M HEPES and 0.1 M NaCl, pH 7.5,
containing bovine serum albumin (BSA; 1 mg/mL), followed by washing in PBS.
Trypsin treatment: cells were incubated for 30 min at 37°C in Hanks’ balanced
salt solution (HBSS) containing 0.25% trypsin along with 100 µg/mL DNAse I
followed by the addition of calf serum to 20% and washing. PI-PLC treatment:
cells were incubated for 30 min at 37°C in PBS containing 0.5 IU/mL PI-PLC
followed by washing. After informed consent, human peripheral blood was
collected from normal volunteer donors into heparinized syringes. PMNs were
isolated after Ficoll-Hypaque density gradient centrifugation as previously
described [13]. In other experiments, unfractionated buffy coat leukocytes were
collected after Dextran sedimentation followed by lysis of contaminating
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erythrocytes as previously described [43]. For some experiments, isolated
PMNs or buffy coat leukocytes were incubated (1 3 107 cells/mL) in Dulbecco’s
PBS containing 1 µM fMLP for 10 min at 37°C, followed by washing in cold
buffer.
Flow cytometric analysis
Based on a soluble receptor binding assay reported by Galon et al. [35], single
cell suspensions (2.5 to 5 3 105 cells in 50 µL) were incubated for varying
times (generally 60 min) at 25°C with B-suPAR (0.2–0.5 µM). Cells were then
washed and incubated for 30 min at 25°C with SA-PE (1 µg/50 µL). After
washing, 5,000 viable cells were analyzed on a Coulter Elite or XL flow
cytometry system (Coulter Electronics, Hialeah, FL). In the case of buffy coat
specimens, lymphocytes, PMNs, and monocytes were gated separately by
forward and side scatter. Competition experiments were performed by pre-
incubating 2.5 to 5 3 105 cells for 60 min at 25°C with varying concentrations
of un-biotinylated suPAR; control proteins such as orosomucoid, murine
monoclonal antibodies (purified IgG or ascites), polyclonal antisera; sugars
(0.15 M); zymosan (1 mg/mL); and EDTA or EGTA (10 mM) before the addition
of 0.2–0.5 µM B-suPAR as described above. In certain experiments, uPA ligand
(either HMW, LMW, or the ATF of uPA) was added (,0.1–20 µM) to the cells
either simultaneously with the addition of B-suPAR or pre-incubated with
B-suPAR for 60 min at 25°C before the addition of the mixture to the cell
suspension.
Indirect immunofluorescent analysis of cell surface antigen expression was
performed as previously published, in which 5 3 105 cells suspended in PBS
containing 1 mg/mL human IgG was incubated for 30 min at 4°C with the
indicated monoclonal and polyclonal reagents, washed, and then incubated for
an additional 30 min at 4°C in PBS containing FITC-conjugated goat




suPAR and 0.05 µM uPA were incubated together at 25°C for 10 min and then
added to 2 3 105 PMA-differentiated and acid-washed THP-1 cells. After
incubation for 60 min at 25°C followed by extensive washing (53), 0.5 3 105
cells in triplicate were assayed for plasminogen activation by incubating in 100
µL of 0.5 mM Spectrozyme PL with 1 µg plasminogen for 2 h at 37°C. The color
developed was read at 405–490 nm with a microplate reader.
Statistics
Comparisons between group means were performed using Student’s t test, where
a P value # 0.05 was considered statistically significant.
RESULTS
Immunoaffinity-purified recombinant suPAR was biotinylated
(B-suPAR) and tested for its capacity to bind to the human
monocytic leukemic cell line, THP-1 and to isolated peripheral
blood PMNs. As shown in Figure 1, when these cells were
incubated for 60 min at 25°C in buffer containing the indicated
concentrations of B-suPAR, the amount of suPAR bound varied
according to the input concentration. Saturation of B-suPAR
binding was approached or reached at concentrations .20 µM
(data not shown). When THP-1 cells were pre-exposed to the
differentiating agent PMA (10 nM) for 24 h, the amount of
B-suPAR bound increased (two- to threefold, n 5 3 experi-
ments). Pre-exposure of isolated PMNs to fMLP (1 µM) for 10
min at 37°C (under conditions that trigger granule exocytosis
and increase the membrane expression of several granule-
associated receptors) had no consistent impact on suPAR
binding, comparing the results of multiple donors. suPAR
binding at 37°C was comparable to that observed at 25°C;
binding at 4°C was consistently less (data not shown). The
kinetics of B-suPAR binding to THP-1 cells and PMNs at 25°C
is shown in Figure 2. A major proportion of B-suPAR binding
Fig. 1. Titration of B-suPAR binding to THP-1 cells and to isolated peripheral blood PMNs. THP-1 cells (A) (either undifferentiated or differentiated by exposure to
10 nM PMA for 24 h at 37°C) and isolated peripheral blood PMNs (B) (either unstimulated or stimulated by exposure to 1 µM fMLP for 10 min at 37°C) were
incubated for 60 min at 25°C with the indicated amounts of B-suPAR. After washing and incubation with SA-PE for 30 min at 25°C, cells were analyzed for bound
B-suPAR as quantitated by their mean fluorescence intensity (in arbitrary units). Similar results were seen in three other experiments.
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is specific as reflected by the competitive inhibition of saturat-
ing quantities of unlabeled suPAR [Fig. 3; also found to occur
with B-suPAR binding at 4°C (data not shown)].
To determine the impact of uPA ligand on the binding of
B-suPAR, we exposed THP-1 or PMN target cells to a fixed
concentration of B-suPAR admixed with varying concentrations
of intact (HMW) uPA. The B-suPAR and uPA were either added
simultaneously to the target cells or were premixed for 1 h at
25°C (to allow complex formation). As shown in Figure 4, the
addition of uPA enhanced the binding of B-suPAR to PMA-
stimulated THP-1 cells with optimal binding occurring at a
B-suPAR:uPA ratio of ,1:30. Pre-incubation of B-suPAR with
uPA resulted in less binding compared with simultaneous
addition of reactants. In contrast, uPA had very little measur-
Fig. 2. Kinetics of suPAR binding to THP-1 cells and to isolated peripheral blood PMNs. THP-1 (A) cells and isolated peripheral blood PMNs (B) (either
unstimulated or pretreated with PMA or fMLP, respectively, as indicated in Fig. 1) were incubated at 25°C for the indicated times with a fixed quantity of B-suPAR
(0.2 µM for THP-1 cells; 0.5 µM for PMNs). After washing and incubation with SA-PE for 30 min at 25°C, the cells were analyzed for bound B-suPAR as indicated by
their mean fluorescence intensity (arbitrary units). Similar results were seen in another experiment.
Fig. 3. Specificity of suPAR binding to THP-1 cells and to isolated peripheral blood PMNs. THP-1 cells (A) and isolated peripheral blood PMNs (B) (either
unstimulated or pretreated with PMA or fMLP, respectively, as indicated in Fig. 1) were pre-incubated for 60 min at 25°C with the indicated amounts of
unbiotinylated suPAR and then, without washing, incubated for an additional 60 min at 25°C with a fixed amount of B-suPAR (0.2 µM for THP-1 cells; 0.5 µM for
PMNs). After washing and incubation with SA-PE for 30 min at 25°C cells were analyzed for bound B-suPAR as indicated by their mean fluorescence intensity
(arbitrary units). Similar results were seen in three other experiments.
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able impact on the binding of B-suPAR to unstimulated THP-1
cells and produced an inhibition of B-suPAR binding to PMNs
(either unstimulated or unstimulated by fMLP). To determine
whether intact HMW-uPA is required to produce maximum
levels of B-suPAR binding to PMA-differentiated THP-1 cells,
the effect of HMW uPA was compared to that of its N-(ATF) and
carboxyl-terminal (LMW) domain fragments (possessing inde-
pendent receptor binding and catalytic activities, respectively).
As shown in Figure 4C, only intact HMW uPA was able to
enhance the binding of B-suPAR to PMA-differentiated THP-1
cells.
Because exogenous HMW uPA influenced the binding of
B-suPAR to THP-1 cells, we sought to determine the effect of
removing endogenous uPA from membrane-associated uPAR
compared with other modifications of the target cell surface,
including treatment with phosphatidyl inositol-specific phospho-
lipase C (PI-PLC) or trypsin (to deplete the membrane of
GPI-anchored and trypsin-sensitive proteins, respectively). As
shown in Figure 5, acid washing of PMA-differentiated THP-1
cells under conditions sufficient to remove greater than 90% of
endogenously bound uPA (Fig. 5B) produced an increase in
B-suPAR binding, which was observed in the absence or
presence of exogenous uPA (Fig. 5A). Treatment of cells with
PI-PLC (which removed 70% of endogenous uPA and approxi-
mately 40% of membrane-associated uPAR) had minimal
impact on suPAR binding. Trypsin treatment (sufficient to
deplete THP-1 cells of nearly all membrane-associated uPA
and uPAR) produced a partial inhibition of specific B-suPAR
Fig. 4. Effect of uPA on the binding of B-suPAR to THP-1 cells and isolated peripheral blood PMNs. THP-1 cells (A) and isolated peripheral blood PMNs (B) (either
unstimulated or pretreated with PMA or fMLP, respectively, as indicated in Fig. 1) were incubated for 60 min at 25°C with a mixture of B-suPAR (0.2 µM for THP-1
cells; 0.5 µM for PMNs) plus the indicated amounts of HMW uPA, which were either added simultaneously to the cell suspensions or pre-incubated together for 60
min at 37°C before their addition to the cells. After washing and incubation with SA-PE for 30 min at 25°C, the cells were analyzed for bound B-suPAR as indicated
by their mean fluorescence intensity (arbitrary units). In panel C, HMW, LMW, or ATF of uPA were added simultaneously to PMA-differentiated THP-1 cells. Similar
results were seen in three other experiments for A and B, and one other experiment for C.
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binding (68 and 52% inhibition, n 5 2 experiments, in the
absence and presence of exogenous uPA, respectively).
Having observed trypsin-sensitive specific binding of suPAR
to THP-1 cells and purified human PMNs, we assayed other
hematopoietic cells for the presence of B-suPAR binding sites.
Among five additional human leukemic cell lines tested
(including those that express or fail to express membrane-
associated uPAR), all displayed the capacity to bind B-suPAR
in a specific fashion (Fig. 6). There was no clear relationship
between the expression or relative density of membrane-
associated uPAR with the amount of B-suPAR bound. When
buffy coat (unpurified) peripheral blood leukocytes were exam-
ined for B-suPAR binding (with or without pre-stimulation with
fMLP, and with and without co-incubation with exogenous uPA),
specific binding was observed for both PMNs and monocytes but
not to lymphoid cells (Fig. 7). The presence of exogenous uPA
enhanced B-suPAR binding to monocytes (similar to that seen
with THP-1 monocytic leukemia cells) but inhibited binding to
PMNs (as seen with density gradient isolated PMNs). Pre-
stimulation of buffy coat cells with fMLP had no consistent
impact on the magnitude of B-suPAR binding.
With the goal of positively identifying putative B-suPAR
binding sites in THP-1 cells and PMNs, we examined the effect
of several monoclonal antibodies along with other reagents that
might influence B-suPAR binding to specific membrane recep-
tor sites. Among the reagents examined were complex sugars
[a-methyl-D-mannopyranside, N-acetyl-D-glucosamine (NADG),
and zymosan], which inhibit the physical linkage between
membrane uPAR and members of the b1, b2, and b3 integrins
[18, 21, 40]; the calcium chelators EDTA and EGTA; murine
mAb specific for CD11a, CD11b, CD11c, CD18, and uPAR
(CD87); and polyclonal antibodies specific for the extracellular
matrix proteins vitronectin, fibronectin, and thrombospondin.
The effect of these agents on B-suPAR binding to PMA-
differentiated THP-1 cells and to unstimulated PMNs is shown
in Figure 8, along with the surface expression of the proteins
specified by the antibodies tested. Based on the combined
results of multiple experiments performed, none of these agents
produced a statistically significant inhibition of B-suPAR
binding to either cell type. In data not shown, the enhanced
binding of B-suPAR to THP-1 cells in the presence of
exogenous uPA was also unaffected. The apparent enhance-
ment of B-suPAR binding to PMNs caused by polyclonal
anti-vitronectin and anti-thrombospondin antibodies (as shown
in Fig. 8) did not reach statistical significance (0.6 , P , 0.7).
suPAR binding to cells that express or lack membrane uPAR
(THP-1 and KG-1a cells, respectively) had no impact on the
expression of cell-associated plasmin-mediated proteolysis
when exogenous sources of uPA and plasminogen were added
(data not shown). However, as shown in Fig. 9, suPAR
pre-incubation was able to diminish the capacity of sub-
saturating amounts of exogenous uPA to bind to membrane-
associated uPAR and catalyze the conversion of plasminogen to
proteolytically active plasmin.
DISCUSSION
In this report we have demonstrated that recombinant suPAR
can bind specifically to human hematopoietic cells that include
normal peripheral blood PMNs and monocytes as well as a
variety of myeloid leukemic cell lines. Among the latter, as
represented by THP-1 cells, binding was markedly enhanced
by prior exposure to the differentiating agent PMA and by the
co-exposure to exogenous uPA ligand. suPAR binding to
monocytes was also increased by uPA but, as in the case with
PMNs, was not affected by brief pre-exposure to soluble
activating agents such as fMLP (under conditions that increase
the surface expression of the b2 integrins and certain other
receptor proteins). Whereas exogenous uPA enhanced suPAR
binding to these monocytic cells, depletion of endogenously
bound uPA by acid washing was associated with an increase in
suPAR binding that was further enhanced by the addition of
Fig. 5. Effect of treatment of PMA-
differentiated THP-1 cells with acid wash-
ing, PI-PLC, or trypsin on the binding of
B-suPAR in the presence or absence of
exogenous uPA. PMA-differentiated THP-1
cells were either untreated, acid washed,
incubated in buffer alone for 60 min at
37°C, incubated in buffer containing PI-
PLC 0.5 IU/mL for 60 min at 37°C, or
incubated in buffer containing trypsin
0.25% for 30 min at 37°C. After washing,
the cells were preincubated for 60 min at
25°C with 2 µM unbiotinylated suPAR or
buffer alone and then, without washing,
incubated for 60 min at 25°C with either
0.2 µM B-suPAR alone or a mixture of 0.2
µM B-suPAR 1 5 µM uPA. After washing
and incubation with SA-PE for 30 min at
25°C, cells were analyzed for bound
B-suPAR as indicated by their mean fluo-
rescence intensity (arbitrary units) (A).
Similar results were seen in two other
experiments. Aliquots of treated cells were
subjected to indirect immunofluorescence
analysis to determine the level of expression of membrane-associated uPAR and uPA (B). The level of expression of uPAR and uPA as seen in untreated cells was set
at 100% (B) so as to compare the relative amounts of these surface proteins after treatment with acid washing, PI-PLC, trypsin, or incubation for 60 min at 37°C.
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Fig. 7. Binding of B-suPAR with or without uPA to buffy
coat lymphocytes, monocytes, and PMNs. Buffy coat
leukocytes were either untreated or pre-incubated for 10
min at 37°C with 1 µM fMLP. The cells were subsequently
pre-incubated for 60 min at 25°C with 5 µM unbiotinyl-
ated suPAR or buffer alone, and then, without washing,
incubated for 60 min at 25°C with 0.5 µM B-suPAR alone
or a mixture of 0.5 µM B-suPAR 1 5 µM uPA. After
washing and incubation with SA-PE for 30 min at 25°C,
cells were analyzed for bound B-suPAR as indicated by
their mean fluorescence intensity (arbitrary units). Similar
results were seen in three other experiments.
Fig. 6. Binding of B-suPAR to a panel of human myeloid leukemia cell lines that express or fail to express membrane-anchored uPAR. The indicated cell lines were
either untreated (U) or pre-incubated for 24 h at 37°C with 10 nM PMA(S). The cells were subsequently incubated for 60 min at 25°C with 2 µM unbiotinylated
suPAR or buffer alone, and then, without washing, incubated for 60 min at 25°C with 0.2 µM B-suPAR. After washing and incubation with SA-PE for 30 min at 25°C,
cells were analyzed for bound B-suPAR as indicated by their mean fluorescence intensity (arbitrary units) (A). The stippled portion of each bar represents nonspecific
B-suPAR binding, whereas the open portion represents specific binding. Similar results were seen in two other experiments. (B) The relative level of
membrane-associated uPAR expressed by these cells as determined by indirect immunofluorescence analysis.
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exogenous uPA. These observations tend to rule out the
possibility that suPAR simply binds to endogenous uPA bound
to membrane-associated uPAR, but may instead bind to
receptor sites that have a higher affinity for uPAR-uPA
complexes. This supports the conclusions made by Higazi et al.
[45] (and corroborated by Chavakis et al. [46]), who demon-
strated that suPAR complexed with uPA binds specifically to
the LM-TK2 fibroblast cell line (genetically deficient in GPI
proteins), leading them to propose that uPA associated with
suPAR induces the appearance of unique binding epitopes
recognized by cell surface receptors. However, unlike the
results of Higazi et al., in which binding of suPAR alone to
fibroblasts was negligible, specific suPAR binding to THP-1
cells and monocytes was not dependent on the development of a
molecular complex with uPA. A lack of uPA dependence was
even more apparent in PMNs in which co-incubation with
exogenous uPA inhibited the binding of suPAR. Clearly, the
binding characteristics of suPAR receptor sites on PMA-
differentiated THP-1 cells differ from those expressed by
PMNs.
Having demonstrated the existence of suPAR binding sites
on a variety of human hematopoietic cells, we performed a
series of experiments designed to better characterize them.
Treatment of THP-1 cells with PI-PLC under conditions that
partially depleted the plasma membrane of uPAR had no
significant effect on suPAR binding, tending to exclude the
possibility that suPAR forms a complex with its membrane
counterpart. This conclusion is further supported by the high
degree of suPAR binding to KG-1a and K562 cells, which do
not express membrane-anchored uPAR. suPAR binding was
diminished by pretreatment of THP-1 cells with trypsin,
consistent with the premise that suPAR receptor sites are cell
surface proteins. We strongly considered the possibility that
members of the b2 integrin family, Mo1 (CD11b/CD18) and/or
p150, 95 (CD11c/CD18) serve as suPAR binding sites. We and
others have shown that in PMNs and monocytes, membrane-
anchored uPAR can form reversible non-covalent linkages with
these two integrins [15, 18, 20, 22] depending on the state of
cellular polarity [19, 20]: uPAR co-associates with Mo1 in
resting non-polarized cells but links up with p150, 95 at the
lamellipodia of polarized migrating cells [20]. These physical
linkages, as detected by receptor co-capping and resonance
energy transfer experiments, are inhibitable by certain complex
sugars [18] (including a-methyl-D-mannopyranoside and
Fig. 8. Effect of sugars, calcium chelators, and anti-integrin or anti-extracellular matrix protein antibodies on the binding of B-suPAR to THP-1 cells and to isolated
peripheral blood PMNs. PMA-differentiated THP-1 cells (A) and unstimulated peripheral blood PMNs (B) were pre-incubated for 60 min at 25°C with the indicated
reagents. Then, without washing, the cells were incubated for 60 min at 25°C with B-suPAR (0.2 µM for THP-1 cells; 0.5 µM for PMNs). After washing and incubation
with SA-PE for 30 min at 25°C, the cells were analyzed for bound B-suPAR as indicated by their mean fluorescence intensity (arbitrary units). The percent inhibition
or enhancement of B-suPAR binding was calculated relative to the amount bound to untreated cells. For those cells pretreated with antibody reagents, aliquots were
washed and stained with FITC-conjugated goat anti-mouse or anti-rabbit IgG to determine the relative amounts of each cell surface protein expressed by the cells (as
shown by their mean fluorescence intensity (arbitrary units).
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NADG), leading us to propose that lectin sites on Mo1 and
possibly p150, 95 provide the structural basis for binding to
uPAR-associated carbohydrate, thereby resulting in inter-
receptor linkage. With this notion in mind, we tested the
capacity of NADG, a-methyl-mannopyranoside, and a variety
of mAbs specific for the b2 integrins to competitively inhibit the
binding of suPAR to PMA-differentiated THP-1 cells and to
unstimulated PMNs. As a precedent for these experiments were
the findings of Galon et al. [35], who reported that the specific
binding of biotinylated soluble CD16b (FcgRIIIb) to Mo1 and
p150, 95 expressed by a variety of human myeloid cells
(supporting the results of our earlier co-capping results that
predicted such a linkage [47]). Surprisingly, we observed no
statistically significant inhibition by the sugars or anti-integrin
antibodies. A variable degree of inhibition was observed when
THP-1 cells and PMNs were pretreated with anti-CD11b mAb
VIM 12, which recognizes an epitope in the lectin domain of
Mo1 [40] (and which inhibits the binding of sCD16b to Mo1
[35]). However, inhibition produced by VIM 12 did not reach
statistical significance compared with isotype-identical nega-
tive control antibodies.
We then explored the possibility that suPAR in the presence
or absence of uPA recognizes membrane-bound vitronectin and
thrombospondin as reported by Higazi et al. [45], who found
that a combination of antibodies specific for these proteins
completely inhibited the binding of the suPAR/uPA complex to
LM-TK2 fibroblasts. The binding of a complex of suPAR/uPA
to vitronectin associated with vascular endothelial cells was
also reported by Chavakis et al. [46]. However, polyclonal
antibodies specific for vitronectin and thrombospondin (alone
or in combination) failed to cause a decrement in suPAR
binding (alone or in combination with uPA); indeed, a trend (not
statistically significant) toward enhancement of suPAR binding
was observed in PMNs pretreated with these antibodies.
On the basis of our results to date, we can make no firm
conclusions about the nature of the cellular binding sites for
suPAR. We cannot as yet exclude the possibility that suPAR
recognizes members of the b2 integrin family inasmuch as
pretreatment with the panel of mAb tested may not be sufficient
to block relevant binding domains expressed by these proteins,
and their affinity for each other may be weak (as suggested by
the reversibility of uPAR’s linkage with both Mo1 and p150,95
[19, 20]). We will explore the possible role of b2 integrins as
receptors for suPAR in subsequent binding studies involving
PMNs from patients with leukocyte adhesion deficiency (who
lack expression of the b2 integrins) and transfectant cell lines
expressing various members of the b2 integrin family.
With respect to the function of suPAR, we previously
reported that exposure of human peripheral blood monocytes
rendered membrane uPAR-negative (by pretreatment with
uPAR antisense oligonucleotides) to recombinant suPAR could
restore the ability of these cells to bind to fibrinogen in a
Mo1-dependent fashion [14]. That is, suPAR could reconstitute
a function normally subserved by the membrane-anchored form
Fig. 9. Effect of suPAR on binding and plasminogen activating capacity of exogenous uPA. PMA-differentiated THP-1 cells were acid-washed to remove
endogenously bound uPA and incubated for 60 min at 25°C with 0.05 µM HMW uPA that had been pre-incubated (10 min at 25°C) with the indicated quantities of
suPAR. Aliquots of these cells were washed and (1) assayed for the quantity of uPA bound as measured by indirect immunofluorescence (filled circles) or (2)
incubated for 120 min at 37°C with plasminogen and Spectrozyme PL to detect cell-associated plasmin activity as measured by a microplate reader (absorbance at
405–490 nm; filled triangles). Identical results were seen in one other experiment.
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of the protein. Conversely, other investigators have found that
suPAR could inhibit uPA-dependent cellular effector responses
(e.g., proliferation and invasion of tumor cells [31, 32]),
suggesting that suPAR competes with membrane uPAR to
down-regulate uPA-dependent signaling events. In experiments
reported here, we have confirmed suPAR’s capacity to scavenge
uPA as reflected by diminished cell-associated plasminogen
activation. Conversely, we found no evidence that suPAR
binding could enhance plasminogen activation by membrane
uPAR-negative cell lines. Therefore, at present we conclude
that suPAR can bind in a specific fashion to a variety of human
hematopoietic cells where its binding is variably influenced by
the differentiation state of the cell and the presence of
exogenous uPA ligand. The precise nature of the binding sites
for uPAR is unresolved but, based on prior co-capping
experiments, might include members of the b2 integrin family
of glycoproteins to which uPAR is functionally linked.
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